Assenagon Asset Management
AVTX icon

Assenagon Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Assenagon Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65
Closed -$79K – 1410
2022
Q4 		$79K Hold
65
– – ﹤0.01% 1336
2022
Q3 		$52K Buy
+65
New +$70.5K ﹤0.01% 1306
2022
Q2 		– Sell
-15
Closed -$31K – 1457
2022
Q1 		$31K Sell
15
-187
-93% -$470K ﹤0.01% 1395
2021
Q4 		$991K Sell
202
-103
-34% -$618K ﹤0.01% 1039
2021
Q3 		$1.92M Sell
305
-7
-2% -$56.7K 0.01% 708
2021
Q2 		$2.94M Buy
312
+168
+117% +$1.41M 0.01% 593
2021
Q1 		$1.25M Buy
+144
New +$1.36M 0.01% 856
2020
Q3 		– Sell
-40
Closed -$300K – 1119
2020
Q2 		$300K Buy
+40
New +$290K ﹤0.01% 1013
2019
Q3 		– Sell
-94
Closed -$1.48M – 846
2019
Q2 		$1.48M Buy
+94
New +$1.42M 0.01% 618

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Assenagon Asset Management's AVTX Position: Q1 2023 in Review

Assenagon Asset Management sold out of Avalo Therapeutics (AVTX) in Q1 2023, closing a stake of 65 shares — an estimated $79K sold.

Assenagon Asset Management first reported a position in AVTX in Q2 2019 and held it in 9 quarters. The position peaked at $2.94M in Q2 2021. 26 funds tracked by Wall St. Rank hold AVTX as of Q1 2023.

  • Assenagon Asset Management reported no remaining Avalo Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 65 Avalo Therapeutics shares in Q1 2023, an estimated $79K.
  • Assenagon Asset Management first reported a position in Avalo Therapeutics in Q2 2019 and held it in 9 quarters.
  • Assenagon Asset Management's Avalo Therapeutics position peaked at $2.94M in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2023.

Based on Assenagon Asset Management's 13F filing for Q1 2023, filed 18 Apr 2023.